Teva's Weltruza — olanzapine LAI — just cleared FDA approval, with management calling a short-notice session to frame it within strategic growth. A new long-acting injectable for the innovative franch
FDA approval of Weltruza plus strategic growth initiatives drive biotech catalyst relevance.
What changed
FDA approval of Weltruza plus strategic growth initiatives drive biotech catalyst relevance.
Why it matters
FDA approval of Weltruza plus strategic growth initiatives drive biotech catalyst relevance. — impact context not separately stored; see What changed.
← Dashboard
Oct 09, 2026 05:48 PM ET